The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.
SBC: Leukogene Therapeutics Inc. Topic: 102
Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomideSBC: FirstString Research, Inc Topic: 102
PROJECT SUMMARY GlioblastomaGBMis an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomideTMZEfforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brainIn contrastsensitizing GBM to TMZ is an appealing strategy because TMZ has excelle ...SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Neuroene Therapeutics, LLC Topic: NINDS
Abstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health